BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...

Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company ...

Analysts fell to the sidelines weighing in on Edwards Lifesciences (EW – Research Report) and SAGE Therapeutics (SAGE – Research Report) with ...

NEW YORK CITY, NY / ACCESS Newswire / February 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...

Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $1.56 per share versus the Zacks Consensus Estimate of a loss of $1.45. This compares to loss of $0.55 per share a year ago. These ...

Steve Coogan has avoided a driving ban after pleading with the judge that it would impact his upcoming TV show - something he has successfully argued before. The Alan Partridge actor, 59, was ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Sage Therapeutics, Inc. (SAGE) reports results for the quarter ended December 2024. While this widely-known ...

But the most important man to please is Stearns' boss, Mets owner Steve Cohen. And in a February 7 article from Fox Sports MLB writer Deesha Thosar, Cohen made his opinion of Stearns' offseason ...

Sage Therapeutics, Inc. (SAGE) shares soared 35.1% in the last trading session to close at $7.50. The move was backed by solid volume with far more shares changing hands than in a normal session.

Vanessa Leroy / Bloomberg via Getty Images Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.

Sage Therapeutics stock opened at $7.44 on Friday. The business’s 50-day simple moving average is $5.64 and its 200 day simple moving average is $7.53. The stock has a market cap of $455.13 ...